

P1523

Abstract (poster session)

Antimicrobial activity of tigecycline on selected Gram-positive and Gram-negative isolates from six European countries; a five-year analysis from the TEST Program 2007-2011

I. Morrissey*, S. Hawser, M. Hackel, C. Zampaloni, D. Hoban, D. Biedenbach, S. Bouchillon, J. Johnson, H. Leister-Tebbe (Epalinges, CH; Schaumburg, US; Collegeville, US)

Background: The Tigecycline Evaluation Surveillance Trial (TEST) monitors the activity of tigecycline and comparators against multiple pathogens collected worldwide. This report compares the antibiotic susceptibility of selected pathogens from Germany (DE), France (FR), Greece (GR), Italy (IT), Spain (ES) & UK collected from 2007 to 2011. Methods: 37,415 key pathogens were collected from the selected countries. MICs were performed as specified by CLSI at each site using prepared broth microdilution panels and interpreted according to EUCAST guidelines. Differences in ESBL rates and % susceptible (%S) were evaluated for statistical significance with the Fisher Exact Test. Results: Overall for *Escherichia coli*, *Klebsiella pneumoniae*, and *K. oxytoca*, ESBL rates were 13.9% in DE and significantly higher in GR, IT and ES ($p < 0.001$). %S for tigecycline and %ESBL are shown below. NA=No breakpoint available Conclusions: Tigecycline exhibited strong in vitro activity against major European pathogens. Among the 6 countries the lowest ESBL rates was detected in FR and the highest in GR. This had no significant effect on tigecycline activity.

N (%S)	DE	FR	GR	IT	ES	UK
<i>A. baumannii</i>	645 (NA)	914 (NA)	182 (NA)	675 (NA)	765 (NA)	39 (NA)
<i>E. aerogenes</i>	216 (94.4)	431 (87.0)	40 (72.5)	267 (96.6)	331 (93.1)	26 (88.5)
<i>E. cloacae</i>	981 (89.4)	1301 (84.6)	197 (76.1)	999 (87.8)	1153 (92.3)	103 (95.2)
<i>E. faecalis</i>	399 (100)	746 (99.7)	103 (97.1)	567 (99.8)	636 (99.4)	55 (100)
<i>E. faecium</i>	332 (99.7)	270 (100.0)	67 (100.0)	260 (98.5)	273 (99.6)	33 (100)
<i>E. coli</i> , ESBL	204 (98)	237 (98.7)	54 (88.9)	419 (99.5)	322 (98.5)	28 (100)
<i>E. coli</i> , non ESBL	1065 (99.3)	1557 (99.2)	258 (98.8)	1052 (99.2)	1296 (99.3)	141 (100)
<i>K. oxytoca</i> , ESBL	14 (100)	12 (91.7)	24 (95.8)	15 (93.3)	7 (85.7)	3 (100)
<i>K. oxytoca</i> , non ESBL	434 (94)	535 (95.3)	87 (65.5)	259 (96.5)	362 (94.5)	52 (100)
<i>K. pneumoniae</i> , ESBL	130 (81.5)	234 (78.2)	201 (88.6)	281 (80.1)	216 (81.0)	27 (85.2)
<i>K. pneumoniae</i> , non ESBL	656 (89.8)	969 (89.7)	0 (-)	783 (89.0)	980 (89.6)	94 (97.9)
<i>P. aeruginosa</i>	1012 (NA)	1399 (NA)	240 (NA)	1139 (NA)	1285 (NA)	129 (NA)
MRSA	286 (100)	401 (100)	110 (100)	433 (100)	442 (100)	40 (100)
MSSA	943 (100)	1299 (100)	140 (100)	905 (100)	1064 (100)	134 (100)
% ESBL	13.9	13.6	32.3	25.5	17.1	16.8